Volume 16, Number 2—February 2010
CME ACTIVITY - Research
Risk Factors for and Estimated Incidence of Community-associated Clostridium difficile Infection, North Carolina, USA1
Table 3
Characteristics | No. (%) persons |
OR (95% CI) | |
---|---|---|---|
Case-patients, n = 73 | Controls, n = 48 | ||
Demographics | |||
Median age, y (range) | 61 (20–101) | 55 (22–87) | |
Female gender | 57 (58) | 34 (71) | |
Non-Hispanic white race |
34 (47) |
35 (73) |
0.32 (0.12–0.7)† |
Coexisting health conditions | |||
Cardiac failure | 20 (27) | 5 (10) | 3.24 (1.12–9.4)† |
GERD | 20 (27) | 2 (4) | 8.7 (1.9–39.1)† |
Hypertension |
36 (49) |
13 (27) |
2.6 (1.2–5.7)† |
Exposures‡ | |||
Antimicrobial drugs | 32 (44) | 8 (17) | 3.9 (1.6–9.5)† |
NSAIDs | 13 (17.8) | 24 (50) | 0.2 (0.1–0.5)† |
Gastric acid suppressors | 15 (21) | 5 (10) | 2.2 (0.75–6.6) |
H2 blockers | 6 (8) | 3 (6) | 1.3 (0.3–5.6) |
Proton pump inhibitor | 9 (12) | 2 (4) | 3.2 (0.7–15.7) |
GERD |
20 (27) |
2 (4) |
8.7 (1.9–39.1)† |
Multivariable analysis§ | |||
Antimicrobial drugs | 9.1 (2.9–28.9)†¶ | ||
NSAIDs | 0.2 (0.1–0.5)†¶ | ||
GERD | 11.2 (1.9–64.2)†¶ | ||
White race | 0.2 (0.05–0.40)†¶ | ||
Cardiac failure | 3.8 (1.1–13.7)†¶ |
*OR, odds ratio; CI, confidence interval; GERD, gastroesophageal reflux disease; NSAIDs, nonsteroidal antiinflammatory drugs.
†p<0.05.
‡Exposures among case-patients were within 3 months prior to the test date; exposures for controls were for all of 2005.
§Goodness-of-fit tests: residual χ2, p = 0.38; Hosmer and Lemeshow, p = 0.77.
¶Adjusted OR.
1Presented in part at the 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12–15, 2006.
Page created: December 13, 2010
Page updated: December 13, 2010
Page reviewed: December 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.